Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1698079

registered interest
date	22/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, what steps her Department is taking to apply the provisions of section 6.26 on exceptional circumstances.
tabling member constituency	Wythenshawe and Sale East
tabling member printed	Mike Kane
uin	20061
answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20062 question first answered 15/04/2024 08:11:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4316 label Biography information for Mike Kane

1698080

registered interest
date	22/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to section 6.26 of the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, whether her Department has been allocated additional resources to consider exceptional circumstances.
tabling member constituency	Wythenshawe and Sale East
tabling member printed	Mike Kane
uin	20062
answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20061 question first answered 15/04/2024 08:11:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4316 label Biography information for Mike Kane

1697850

registered interest
date	21/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genetics: Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many patients in the South West have been eligible for pre-implantation genetic testing for monogenic disorders in each of the last five years.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	19828
answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>Pre-implantation Genetic Testing (PGT) is used to identify genetic anomalies in embryos created through in-vitro fertilisation. Over 600 genetic conditions can currently be tested for using this technique, as licensed by the Human Fertilisation and Embryology Authority. NHS England has commissioned five centres to provide PGT to patients in England. The number of PGT cycles undertaken has increased from 223 patients in 2009 to 620 in 2019, but NHS England does not have access to data that describes the geographical profile of the people that have used the National Health Service or privately commissioned PGT services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 10:39:37 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1491 label Biography information for Kerry McCarthy